Biofunctional magnetic nanoparticles as contrast agents for magnetic resonance imaging of pancreas cancer

Microchimica Acta

Volumn 167, Issue 1, 2009, Pages 27-34

  Huang, Mingming ^a   Qiao, Zhongwei ^b   Miao, Fei ^b   Jia, Nengqin ^a   Shen, Hebai ^a  

^a SHANGHAI NORMAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; CA19 9 monoclonal antibody; Contrast agents; Dextran coated magnetic nanoparticles; Magnetic resonance imaging; Pancreas cancer cells

Indexed keywords

EID: 70350702839     PISSN: 00263672     EISSN: 14365073     Source Type: Journal    
DOI: 10.1007/s00604-009-0210-y     Document Type: Article

References (40)

1. Wu EX, Tang H, Jensen JH (2004) Applications of superparamagnetic iron oxide nanoparticles in animal studies-Review. NMR Biomed 17:478.
2. Wang YXJ, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319.
3. Neuberger T, Schöpf B, Hofmann H, Hofmann M, von-Rechenberg B (2005) Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. Magn Magn Mater 293:483.
4. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R (2000) Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410.
5. Gupta AK, Curtis AS (2004) Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci: Mater Med 15:493.
6. Moore A, Marecos E, Bogdanov A Jr, Weissleder R (2000) Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticels in a rodent model. Radiology 214:568.
7. Josephson L, Tung CH, Moore A, Weissleder R (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjugate Chem 10:186.
8. Choi H, Choi SR, Zhou R, Kung HF, Chen IW (2004) Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11:996.
9. Tsourkas A, Shinde-Patil VR, Kelly KA, Patel P, Wolley A, Allport JR, Weissleder R (2005) In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjugate Chem 16:576.
10. Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R (2005) The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers. Anticancer Res 25:3665.
11. Martina MS, Fortin JP, Menager C, Clement O, Barratt G, Grabielle-Madelmont C, Gazeau F, Cabuil V, Lesieur SJ (2005) Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. Am Chem Soc 127:10676.
12. Blasberg RG (2003) Molecular imaging and cancer. Mol Cancer Ther 2:335.
13. Artemov DJ (2003) Molecular magnetic resonance imaging with targeted contrast agents. Cell Biochem 90:518.
14. Kroft LJ, de-Roos A (1999) Blood pool contrast agents for cardiovascular MR imaging. Magn Reson Imaging 10:395.
15. Bonnemain B (1998) Superparamagnetic agents in magnetic resonance imaging: physico-chemical characteristics and clinical applications. Drug Targeting 6:167.
16. Bellin MF, Beigelman C, Precetti-Morel S (2000) Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol 34:257.
17. Aime S, Cabella C, Colombatto S, Geninatti Crich S, Gianolio E, Maggioni F (2002) Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imaging 16:394.
18. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA (2003) Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229:838.
19. Kaim AH, Wischer T, O'Reilly T, Jundt G, Frohlich J, von-Schulthess GK, Allegrini PR (2002) MR imaging with ultrasmall superparamagnetic iron oxide particles in experimental soft-tissue infections in rats. Radiology 225:808.
20. Jung CW, Jacobs P (1995) Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 13:661.
21. Benderbous S, Corot C, Jacobs P, Bonnemain B (1996) Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol 3:292.
22. Moeser GD, Roach KA, Green WH, Laibinis PE, Hatton TA (2001) Waterbased magnetic fluids as extractants for synthetic organic compounds. Ind Eng Chem Res 41:4739.
23. Mendenhall GD, Geng YP, Hwang J (1996) Optimization of long-term stability of magnetic fluids from magnetite and synthetic polyelectrolytes. Coll Interf Sci 184:519.
24. Ditsch A, Laibinis PE, Wang DIC, Hatton TA (2005) Controlled clustering and enhanced stability of macromolecule-coated magnetic nanoparticles. Langmuir 21:6006.
25. Kim DK, Mikhaylova M, Zhang Y, Muhammed M (2003) Protective coating of superparamagnetic iron oxide nanoparticles. Chem Mater 15:1617.
26. Zaitsev VS, Filimonov DS, Presnyakov IA, Gambino RJ, Chu B (1999) Physical and chemical properties of magnetite and magnetite-macromolecule nanoparticles and their colloidal dispersions. Coll Interf Sci 212:49.
27. Caruso F (2001) Nanoengineering of particle surfaces. Adv Mater 13:11.
28. Xavier M, Ralph W, Lee J (2006) Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjugate Chem 17:905.
29. Freeny PC (1988) Radiology of the pancreas: two decades of progress in imaging and intervention. AJR Am J Roentgenol 150:975.
30. Lutterotti L, Gialanella S (1997) X-ray diffraction characterization of heavily deformed metallic specimens. Acta Matet 46:101.
31. Li XZ, Lin W, Zhou C, Guan TT, Li J, Zhang YH (2007) Preliminary studies of application of CdTe nanocrystals and dextran-Fe3O4 magnetic nanoparticles in sandwich immunoassay. Clin Chim Acta 378:168.
32. Zhu Z, Grütter P (2004) Imaging, manipulation, and spectroscopic measurements of nanomagnets by magnetic force microscopy. MRS Bull 29:457.
33. Gupta AK, Curtis AS (2004) Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. Mater Sci: Mater Med 15:493.
34. Tiefenauer LX, Tschirky A, Kuhne G, Andres RY (1996) In vivo evaluation of magnetite nanoparticles for use as a tumour contrast agent in MRI. Magn Reson Imaging 14:391.
35. Choi H, Choi SR, Zhou R, Kung HF, Chen IW (2004) Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11:996.
36. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K (2004) MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 22:843.
37. Kondo S, Muroya M, Fujii K (1974) The thermal behavior of silanol groups of silica gel as studied by infrared spectroscopy. Bull Chem Soc Jpn 47:553.
38. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH, Yoon S, Kim KS, Shin JS, Suh JS, Cheon S (2005) In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. Am Chem Soc 127:12387.
39. Schumann-Giampieri G (1993) Liver contrast media for magnetic resonance imaging. Invest Radiol 28:753.
40. Ferrucci JT, Stark DD (1990) Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 155:943.